Phaseline

Companies › Shenzhen MagicRNA Biotechnology

Shenzhen MagicRNA Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HN2301 injection
in vivo CAR-T cell therapy
–Phase 1Systemic Lupus ErythematosusDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06801119HN2301 injectionPhase 1Systemic Lupus ErythematosusImmunologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.